Q-omics provides the consensus-scored RAP1BL profile across patient tissues and cancer cell-line models. RAP1BL expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RAP1BL is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, RAP1BL RNA expression shows 18,225 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SKCM, HNSC, and ACC as cancer lineages where RAP1BL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAP1BL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAP1BL survival associations across molecular data types. RAP1BL RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAP1BL RNA expression–survival associations across cancer types. High RAP1BL expression shows unfavorable associations in UVM, LGG and MESO, but favorable associations in SKCM, KIRC and READ. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RAP1BL RNA expression.
This table summarizes RAP1BL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RAP1BL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAP1BL shows lower tumor expression in KICH, THCA, READ and BLCA and higher tumor expression in HNSC and CHOL. The HNSC box plot shows higher RAP1BL RNA expression in tumor versus normal tissue (log2 FC = +0.945, t-test p < 0.001).
This table shows molecular features associated with RAP1BL in patient tissues and cancer cell lines. In patient samples, RAP1BL shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
